Cervical Cancer: Treatment Options, Fertility & Specialist Care

Record which staging edition was used. A drug label based on FIGO 2014 stage III–IVA cannot be matched simply to every modern FIGO 2018 stage III case: a tumor classified IIIC only because of nodes may have a different original local stage.

Very early disease may be managed with a cone excision or hysterectomy depending on invasion, margins and other risk factors. Larger early tumors may require more extensive surgery and nodal assessment. The SHAPE randomized trial supports less radical hysterectomy in carefully selected low-risk tumors no larger than 2 cm with limited stromal invasion; that result does not mean every small tumor qualifies.

Fertility-sparing surgery is a separate decision from reducing surgical radicality. Cone excision or trachelectomy may preserve the uterus in selected cases, with careful margin and node assessment. A hysterectomy, even a simple one, removes the uterus and does not preserve the ability to carry a pregnancy.

Discuss egg or embryo preservation and the likely effects of pelvic treatment before therapy starts. Ovarian transposition may reduce ovarian radiation exposure in selected patients, but does not guarantee fertility or protect the uterus from radiation.

Definitive treatment commonly combines external-beam radiation, concurrent platinum-based chemotherapy and brachytherapy. Brachytherapy places radiation close to the tumor and can deliver a focused dose while limiting nearby-organ exposure. It needs advance scheduling and expertise; extra external-beam radiation is not an automatic equivalent replacement.

The current US pembrolizumab label includes combination with chemoradiotherapy for locally advanced FIGO 2014 stage III–IVA cervical cancer. This setting does not require the PD-L1 CPS threshold used for its recurrent/metastatic indication. The clinical team should map the person's actual anatomy and stage to the label.

Kidney impairment, urinary obstruction and anemia may need treatment before or during the plan. Ask how the team will keep radiation on schedule, manage side effects and deliver the full brachytherapy course.

The INTERLACE randomized trial tested six weeks of weekly carboplatin and paclitaxel immediately before standard chemoradiation in a defined locally advanced population and found improved survival outcomes. This supports discussing a specific induction strategy for suitable patients, rather than giving an arbitrary course of chemotherapy before radiation.

Its population and treatment sequence differ from immunotherapy-plus-chemoradiation studies. Combining all promising approaches together has not automatically been proven better. The team should explain which evidence fits the case and how to avoid delaying definitive local treatment.

First determine whether disease is an isolated pelvic recurrence, limited spread or more widespread progression. Previous radiation fields and doses are essential. Selected local recurrences may still be considered for salvage surgery or specialist reirradiation; these can be complex procedures with substantial functional consequences.

• In the US, pembrolizumab with chemotherapy, with or without bevacizumab, is approved for persistent, recurrent or metastatic disease with PD-L1 CPS ≥1 using an FDA-authorized test. Its single-agent indication also requires CPS ≥1 and progression on or after chemotherapy.
• In the EU, cemiplimab monotherapy is an approved option for adults with recurrent or metastatic cervical cancer progressing on or after platinum chemotherapy, without a PD-L1 threshold in that indication. Regional approvals are not interchangeable.
• US tisotumab vedotin (Tivdak), an antibody–drug conjugate, is approved for adults with recurrent or metastatic cervical cancer progressing on or after chemotherapy. Eye examinations and preventive eye care are required; bleeding and neuropathy also need attention.

Bevacizumab suitability requires particular attention to bleeding, fistula risk, healing and previously irradiated tissues. Previous immunotherapy, organ function and any actionable tumor findings also influence the next choice.

Cadonilimab: a treatment pathway available in China

Cadonilimab targets PD-1 and CTLA-4. Its Chinese prescribing information includes first-line use with paclitaxel and platinum chemotherapy, with or without bevacizumab for persistent, recurrent or metastatic cervical cancer, and single-agent treatment after platinum failure for recurrent/metastatic disease. These indications do not require PD-L1 positivity. Previous immune treatment, autoimmune conditions and the risks of the full combination still matter, including immune-related inflammation of organs such as the lungs or bowel. Chirona arranges specialist eligibility review and coordinates treatment at the selected partner hospital.

Fudan University Shanghai Cancer Center · Shanghai, China

Offers fertility-sparing cervical surgery and gynecologic brachytherapy, including interstitial treatment. Useful questions are whether the uterus can be preserved and how the full radiation course will be delivered.

MD Anderson Cancer Center · Houston, United States

Its gynecologic cancer and oncofertility services support review of treatment and reproductive priorities. Ask for the surgical and radiation options to be assessed together.

Memorial Sloan Kettering Cancer Center · New York, United States

Provides multidisciplinary cervical cancer care and fertility-sparing surgery for selected early cases. A review can clarify surgical extent, lymph-node assessment and treatment after recurrence.

HPV testing and cervical cytology identify risk or cell abnormalities. Colposcopy allows directed biopsy; an excisional specimen such as a cone biopsy may be needed to assess invasion and margins. CIN or a high-grade precancerous lesion is not automatically invasive cancer.

The main invasive types are squamous cell carcinoma and adenocarcinoma. Some adenocarcinomas are HPV-independent, and rare neuroendocrine cancers need a distinct plan. Ask for the exact histology, invasion depth, lymphovascular invasion and margins rather than relying only on the word 'cervical cancer'.

Pelvic MRI helps assess local extent; CT or PET/CT may assess nodes and distant sites. Examination, kidney function and pathology contribute to planning. Imaging and biopsy answer complementary questions.

Most cervical cancers develop after persistent high-risk HPV infection. HPV is common, and most infections do not become cancer. A positive result cannot determine when an infection was acquired or be used to draw conclusions about a partner. Vaccination and screening prevent many cancers, but vaccination does not treat an established tumor.

Bleeding after sex, between periods or after menopause, unusual discharge and pelvic pain need assessment. Early disease may have no symptoms. Heavy bleeding with dizziness, severe pain or trouble passing urine needs urgent care rather than waiting for the next screening appointment.

Pelvic treatment can cause bowel and bladder changes, vaginal dryness or narrowing, early menopause and lymphedema. Ask about pelvic-floor care, vaginal rehabilitation and symptom treatment. A plan should respect comfort and consent; pain or bleeding during sexual activity deserves assessment.

Report new bleeding, persistent pelvic or back pain, leg swelling, urinary difficulty or unexplained weight loss between scheduled visits. Follow-up reviews both recurrence and treatment effects; the right investigation depends on the symptom and previous therapy, not only the calendar.

• Bring biopsy/cone pathology, the stated FIGO edition and stage, MRI/PET images and nodal findings.
• After radiotherapy, obtain the complete external-beam and brachytherapy plan and dose records.
• Include prior systemic medicines, response, PD-L1 or other relevant tests, and fertility or functional priorities.